Compare Comcast Corporation (CMCSA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Comcast Corporation trades at $25.44 (market cap $91.02B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Comcast Corporation pays a 5.15% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Comcast Corporation nearer its low. Which is the better fit depends on your goals.
| CMCSA | XBI | |
|---|---|---|
Market Cap | $91.02B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $32.50 | $164.28 |
52-Week Low | $21.92 | $86.92 |
Enterprise Value | $173.74B | — |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.35, up 0.6% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.04 versus $0.97 expected, driven by wireless growth and Peacock profitability. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff. Fundamentals show robust cash flow generation, with 2025 operating cash flow at $33.64 billion, and attractive valuation metrics including a P/E of 8.22 and EV/EBITDA of 5.09.
The outlook for CMCSA is positive, supported by analyst consensus with a $27.78 price target and 55.74% buy ratings. Investment opportunities include the potential upside from the NBCUniversal separation and sustained dividend payments. Key risks involve competitive pressures in broadband, theme park volatility, and integration challenges from corporate restructuring. The stock offers value with solid fundamentals but faces execution risks in a dynamic media landscape.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
